Gilead Sciences Inc buy gerihouse
Start price
29.04.16
/
50%
€80.73
Target price
28.03.17
€100.00
Performance (%)
-20.63%
End price
28.03.17
€62.31
Summary
This prediction ended on 28.03.17 with a price of €62.31. The price of Gilead Sciences Inc has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -20.63%. gerihouse has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Gilead Sciences Inc | -0.048% | -0.048% | -20.127% | 15.854% |
| iShares Core DAX® | 1.804% | -0.748% | 13.168% | 16.408% |
| iShares Nasdaq 100 | -0.182% | -3.412% | 39.976% | 43.502% |
| iShares Nikkei 225® | 0.413% | -7.381% | 18.776% | 2.874% |
| iShares S&P 500 | 0.664% | -1.941% | 28.141% | 42.155% |
According to gerihouse what are the pros and cons of Gilead Sciences Inc for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Capable Management
Top 10 in its market
Known brand
Future proof or reliable business model
Small cyclical dependencies
Cons
Comments by gerihouse for this prediction
In the thread Gilead Sciences Inc diskutieren
Nicht so schlecht
Kursrücksetzer kaufen!
Aktienanalystin Alethia Young von der Investmentbank Credit Suisse rechnet laut einer aktuellen Aktienanalyse zu den Aktien des US-Biotechkonzerns Gilead Sciences Inc. (ISIN: US3755581036, WKN 885823, Ticker-Symbol: GIS, Nasdaq-Symbol: GILD) weiterhin mit einer überdurchschnittlichen Kursentwicklung.
Gilead Sciences Inc. dürfte saubere Quartalszahlen vorlegen. Bei den Umsätzen bestehe sogar die Möglichkeit einer positiven Überraschung.
Die Analysten der Credit erhöhen die Schätzungen auf Grund der Berücksichtigung der potenziellen Käufe durch das Veteranenministerium (VA) und der Erwartung, dass Konkurrenzprodukte geringere Einflüsse auf das Hepatitis C-Geschäft von Gilead Sciences hätten.
Die Verschreibungsdaten würden im sequenziellen Vergleich 5 bis 10% zurückliegen. Der VA-Bereich könnte jedoch für ein Übertreffen der Prognosen sorgen.
In ihrer Gilead Sciences-Aktienanalyse bestätigen die Analysten der Credit das Rating "outperform" und erhöhen das Kursziel von 116,00 auf 120,00 USD.
(Vom Mitglied beendet)
Stopped prediction by gerihouse for Gilead Sciences Inc
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€70.87
08.06.20
08.06.20
€65.00
04.11.21
04.11.21
-18.67%
05.11.21
05.11.21
Could be worthwhile Investment >10% per year
Capable Management
Top 10 in its market
Known brand
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€70.51
18.05.20
18.05.20
€90.00
30.05.20
30.05.20
-4.08%
30.05.20
30.05.20
Could be worthwhile Investment >10% per year
Capable Management
Top 10 in its market
Known brand
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€77.59
02.05.20
02.05.20
€85.00
16.05.20
16.05.20
-8.49%
16.05.20
16.05.20
Could be worthwhile Investment >10% per year
Capable Management
Top 10 in its market
Known brand
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€78.80
20.04.20
20.04.20
€85.00
02.05.20
02.05.20
-1.54%
02.05.20
02.05.20
Could be worthwhile Investment >10% per year
Capable Management
Top 10 in its market
Known brand
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€68.19
28.02.20
28.02.20
€85.00
20.04.20
20.04.20
15.56%
20.04.20
20.04.20
Could be worthwhile Investment >10% per year
Capable Management
Top 10 in its market
Known brand
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€57.14
28.10.19
28.10.19
€70.00
09.11.19
09.11.19
2.28%
09.11.19
09.11.19
Could be worthwhile Investment >10% per year
Capable Management
Top 10 in its market
Known brand
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€59.55
16.09.19
16.09.19
€65.00
28.10.19
28.10.19
-4.05%
28.10.19
28.10.19
Could be worthwhile Investment >10% per year
Capable Management
Top 10 in its market
Known brand
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€59.30
03.05.19
03.05.19
€70.00
27.05.19
27.05.19
1.57%
27.05.19
27.05.19
Could be worthwhile Investment >10% per year
Capable Management
Top 10 in its market
Known brand
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€71.09
03.10.17
03.10.17
€76.00
25.06.18
25.06.18
-12.90%
25.06.18
25.06.18
Could be worthwhile Investment >10% per year
Capable Management
Top 10 in its market
Known brand
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€59.60
21.06.17
21.06.17
€72.16
30.08.17
30.08.17
21.12%
30.08.17
30.08.17
Could be worthwhile Investment >10% per year
Capable Management
Top 10 in its market
Known brand
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€75.79
08.02.16
08.02.16
€100.00
28.04.16
28.04.16
14.98%
28.04.16
28.04.16
Could be worthwhile Investment >10% per year
Capable Management
Top 10 in its market
Known brand
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€99.55
04.11.15
04.11.15
€115.00
29.01.16
29.01.16
-22.56%
29.01.16
29.01.16
Could be worthwhile Investment >10% per year
Capable Management
Top 10 in its market
Known brand
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€88.52
12.10.15
12.10.15
€100.00
27.10.15
27.10.15
12.97%
27.10.15
27.10.15
Could be worthwhile Investment >10% per year
Capable Management
Top 10 in its market
Known brand
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€86.75
24.08.15
24.08.15
€100.00
21.09.15
21.09.15
9.95%
21.09.15
21.09.15
Could be worthwhile Investment >10% per year
Capable Management
Top 10 in its market
Known brand
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€93.74
04.05.15
04.05.15
€110.00
29.06.15
29.06.15
11.35%
29.06.15
29.06.15
Could be worthwhile Investment >10% per year
Capable Management
Top 10 in its market
Known brand
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€85.69
05.02.15
05.02.15
€100.00
18.03.15
18.03.15
7.04%
18.03.15
18.03.15
Could be worthwhile Investment >10% per year
Capable Management
Top 10 in its market
Known brand
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€81.88
08.09.14
08.09.14
€95.00
28.01.15
28.01.15
12.25%
28.01.15
28.01.15
Could be worthwhile Investment >10% per year
Capable Management
Top 10 in its market
Known brand